131 related articles for article (PubMed ID: 10211548)
1. Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Sankar A; Thomas DG; Darling JL
Anticancer Drugs; 1999 Feb; 10(2):179-85. PubMed ID: 10211548
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide. A new option for high-grade astrocytomas.
Schwenka J; Ignoffo RJ
Cancer Pract; 2000; 8(6):311-3. PubMed ID: 11898150
[No Abstract] [Full Text] [Related]
3. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
4. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a side population of astrocytoma cells in response to temozolomide.
Chua C; Zaiden N; Chong KH; See SJ; Wong MC; Ang BT; Tang C
J Neurosurg; 2008 Nov; 109(5):856-66. PubMed ID: 18976075
[TBL] [Abstract][Full Text] [Related]
6. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Sun S; Wong TS; Zhang XQ; Pu JK; Lee NP; Day PJ; Ng GK; Lui WM; Leung GK
J Neurooncol; 2012 Mar; 107(1):89-100. PubMed ID: 21979894
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine.
Lewandowicz GM; Harding B; Harkness W; Hayward R; Thomas DG; Darling JL
Eur J Cancer; 2000 Oct; 36(15):1955-64. PubMed ID: 11000577
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
10. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ
Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide in malignant gliomas.
Yung WK
Semin Oncol; 2000 Jun; 27(3 Suppl 6):27-34. PubMed ID: 10866347
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
13. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Kast RE; Ramiro S; Lladó S; Toro S; Coveñas R; Muñoz M
J Neurooncol; 2016 Feb; 126(3):425-31. PubMed ID: 26603162
[TBL] [Abstract][Full Text] [Related]
14. Activity of temozolomide against human tumor colony-forming units.
Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
16. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Lefranc F; James S; Camby I; Gaussin JF; Darro F; Brotchi J; Gabius J; Kiss R
J Neurosurg; 2005 Apr; 102(4):706-14. PubMed ID: 15871514
[TBL] [Abstract][Full Text] [Related]
17. Fasting enhances the response of glioma to chemo- and radiotherapy.
Safdie F; Brandhorst S; Wei M; Wang W; Lee C; Hwang S; Conti PS; Chen TC; Longo VD
PLoS One; 2012; 7(9):e44603. PubMed ID: 22984531
[TBL] [Abstract][Full Text] [Related]
18. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
19. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Trippoli S; Pelagotti F; Messori A; Vacca F; Vaiani M; Maltoni S
Drugs R D; 2003; 4(5):285-91. PubMed ID: 12952497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
